🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
26.04
+0.20 (0.77%)
At close: Nov 18, 2026, 4:00 PM EST
26.24
+0.20 (0.77%)
After-hours: Nov 18, 2026, 5:49 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

ZW209’s Roche partnership, a diversified capital strategy and novel multi-specific programs are central to the outlook. Key catalysts include zanidatamab studies and a 2027 phase III pasritamig readout.

Phoebe Tan
Analyst, Jefferies

Perfect. Hi, everyone. My name is Phoebe Tan, and I work with Akash Tewari. Today, I have the pleasure of hosting Zymeworks, and I will hand it off to Ken, the CEO, for some intro remarks.

Ken Galbraith
CEO, Zymeworks

That is great. Happy to be back here again. Thanks for the invitation. 2026 has been a great year for Zymeworks so far, and there are six weeks left in the year, so we are not finished yet. It is like we have been able to show from the beginning of the year just executing the different parts of this diversified model of biotech that we believe strongly in. I think some of the transactions and things we have done this year can provide a good example of what we think we can do.

For 2027 and 2028, you are just going to see more of the same, but just more of it, better, faster, higher quality as we move to build Zymeworks the way that we have laid out last year at your conference.

Phoebe Tan
Analyst, Jefferies

Perfect. I wanted to start with ZW209, your trispecific DLL3, that you just did a licensing deal with Roche. First, can you talk about what excites you about this asset and where you think it may differentiate versus the other DLL3 approaches, ADCs, and TCEs? Also, what early data could you maybe indicate that Roche might have seen that kind of got them excited as well?

Ken Galbraith
CEO, Zymeworks

Yeah, great. I think we are excited about a bunch of things about ZW209 and the Roche deal. I think first and foremost, our little 100-person R&D group in Vancouver continues to create differentiated molecules and do things that no one else has been able to do, or no one else seems to be able to copy.

I think beyond zanidatamab and pasritamig, I think ZW209 is a really unique co-stim platform, building in two signals into one biologic. Roche certainly validated our approach of being different by having you know they had access to other trispecifics they could have- chosen inside Roche, or externally, from around the world. But they found what they were looking for in Vancouver, and I think they were impressed by the preclinical data and the quality of it that will hopefully translate into the clinic.

But really, it's just a unique, divergent approach that we've taken that no one else seems to be able to do with their platforms. That's really exciting. I think partnering with Roche before going to clinical studies was definitely a strategic choice for us, rather than taking it further ourself. I think as we look at small cell lung cancer becoming much more competitive, also the fact that maybe combination strategies will win the day with patients.

We've certainly seen people take ADC approaches, T-cell engager approaches. We're certainly taking the idea of building signal one and signal two into a single molecule, also the impact of immunotherapy or maybe two out of those three, or potentially all three of those being used in combination. I think partnering with Roche, who already has access to the other components which could be added to ZW209, is pretty exciting.

I think we were really excited by the data that we saw at SITC last year, or last week, or two weeks ago maybe, from our partner J&J, looking at combining pasritamig, which is a CD3 T-cell engager against KLK2 prostate cancer, with a PSMA CD28. So a signal one, signal two approach in how we think about being more efficient with T-cell engagers and mobilizing more when they're exhausted, or mobilizing more initially and making them more functional approach.

That was interesting, as in two different bispecific antibodies combined together. But we certainly think it validates this idea that a signal two can be beneficial, versus an initial activation of T-cells by CD3. We're hoping we can show that in a single biologic structure, with our controlled, conditionally activated CD28 approach.

Phoebe Tan
Analyst, Jefferies

Great. When should we expect initial data, and what would you want to see that you would consider exciting?

Ken Galbraith
CEO, Zymeworks

Yeah, I know you don't like the answer. We just won't give any guidance on when you'll see data. We've stuck very firmly to what we think is the right approach, which is any clinical data that's presented has to have something meaningful to say, and it's always in a peer-reviewed format.

You won't see it in a press release. You won't see it at an R&D day. You'll see it in a peer-reviewed format with the right amount of integrity behind that data, and when something meaningful has been seen. Obviously, if you look at our prior compounds we put in the clinic the last couple years, we go very fast in dose escalation, dose optimization to get that answer.

Certainly, having Roche allow us to start the clinical study this year in the dose escalation is, I think, a sign that they like that momentum and speed and quality we can generate to get enough data right away to make answers, to make decisions about what to do next. And so w e'll bring that efficiency that we've built in our clinical trial unit to Roche, which is kind of ironic. I think we can just keep the momentum of that program going really quickly.

Phoebe Tan
Analyst, Jefferies

Okay. Understood. In general, this seems like one potential deal structure for Zymeworks in your early pipeline. Can you talk about any other potential deal structures, partnerships, or full sale? You are partnering and you are working on the phase I together. How should we look at potential future deals?

Ken Galbraith
CEO, Zymeworks

Yeah, I think it is a good question. There are two important things at Zymeworks that I think differentiate us a little bit that we pay attention to. One is, we have this financial foundation with our commercial royalties and assets, which gives us a really nice financial foundation, which every day is becoming more predictable, more durable.

That is one part of it. The second part is we have a ridiculously productive and efficient R&D group, that continues to create unique and differentiated molecules that no one else is working on. And then I think when we think about that, we have to find a way to move a pretty broad and diverse portfolio forward, but just not on our own balance sheets.

We make very careful decisions about what we finance ourselves off our own balance sheet and a part of that financial foundation, and keep things unencumbered, and we will always have a segment there. We think very clearly about where a partnership might be the way to access capital and resources and speed and competitive advantage, which you can see with the Roche deal with ZW209.

Then we also have this other element where we think there might be parts of our portfolio, which is pretty rich, to carve out and create a dedicated team, dedicated capital in a separate entity that we can keep an equity share in and a royalty obligation to the underlying assets and move that forward. We have certainly seen that with our pan-RAS ADC portfolio, which we worked on for two years.

First scientific disclosure was in April at AACR, and that looks like a whole new company with four development candidates in our pan-RAS inhibitor ADCs. Only made three of them public. But that seems like it should be in a dedicated entity to get the right attention, the right capital, move quickly, keep it unencumbered longer, but unencumbered off our balance sheets. We won't own all of it, but we'll own a significant stake of it.

Through our royalty and equity interest. I think for us, the secret is, how do we continue to move all this exciting R&D forward, but find different ways to do it so we can manage the amount of capital, and the risk that our shareholders retain, and the upside that's retained from continued successful development of really innovative structures?

Phoebe Tan
Analyst, Jefferies

Yeah. On that point, how do you balance between product expansion with acquisitions, like Theravance, or partnering your early assets, or share buybacks? I guess, how are you thinking about capital allocation in general?

Ken Galbraith
CEO, Zymeworks

Yeah. It's nice to be in a position where we see ourselves having excess cash flow to think about capital allocation going forward, as far as we can see. As long as our business stays on track, that's the mindset we have. I think we use partnerships like with Roche or acquisitions like Theravance just to change the nature and shape of the R&D portfolio we have, versus what it would grow to organically. As you can see with Roche, we've been able to find a partner who's very excited about moving that asset forward with their capital.

Obviously, that saves us some money we would have invested in phase I that we can reallocate somewhere else. Had a nice $55 million upfront payment that we can redeploy into another R&D asset. It just changed the nature and shape of that. We are obviously sharing risk with Roche going forward and sharing upside in a certain way.

On the acquisition side, our acquisition of Theravance this year brought us not only a commercial asset to just improve the financial foundation that is already very strong with us, but gives us access to 30 years of science at Theravance, and trying to find a way to find maybe an R&D asset or two that is interesting, that can be additive to what we have been able to generate internally through our own R&D operations. These acquisitions and partnerships are just a way to change the nature and shape of the R&D portfolio we have.

Obviously, the returns and retaining upside, but also the risk tolerance of our shareholders for the type of risks that go along with translating preclinical innovations into the clinic and then moving forward into clinical studies. We match that with the idea that excess cash flow can be returned to shareholders on a regular basis. We have been doing that for more than two years. I think since we started in the summer of 2024, we bought back 17% of the company for our own shareholders.

I think deploying capital with a long-term model makes a lot of sense for us. And we still are able to fund all the interesting R&D opportunities we have. We are able to fund M&A through our own capital, but also leveraging it with additional capital sources outside.

We think this mix of funding the right R&D for the right reasons, being acquisitive to add both commercial assets and R&D assets, while at the same time respecting shareholders and returning capital back to them on a regular basis that is generated from the business, is a really interesting model.

If we get that right and we get the mix right of what to keep unencumbered ourselves from our R&D perspective, what to partner and what to carve out, and we do that in the right mix, that is a really interesting construct. I know it is diversified, it is not simplistic, it is not one catalyst to explain to shareholders. There is a benefit in having a diversified business, of having multiple ways to build value for shareholders over the long term.

Phoebe Tan
Analyst, Jefferies

Perfect. And just to touch on Theravance, I guess, how is launch going post-acquisition, and how do you expect this to evolve over the next year?

Ken Galbraith
CEO, Zymeworks

Yeah, it is a really interesting asset. It has obviously been on the market for seven or eight years, so I think it is predictable. The partnership with Viatris allowed Theravance, now us, to participate in the commercialization of the product through a US co-promotion force that is hospital-based.

We have some impact on top line. It is a profit-sharing joint venture, it is not a royalty share, so we like the ability of having some variability in how that might be constructed. It has got a pretty long, extended patent life that is useful, that is out another 12 years +, which is great. It is really the only one of its kind in the U.S. So from that perspective, again, it is something where we are on our own in terms of differentiation of that asset.

So it is consistent with the way we think about zanidatamab being unique and differentiated, not really been copied since. Pa sritamig being so unique and differentiated as a T-cell engager in prostate cancer. ZW209 being very unique and differentiated in the way that we build co-stimulation into a trispecific antibody. It is consistent with that theme, but I think it is a predictable, durable source of cash flow for us, and we can decide how to use that capital in our allocation strategy.

Phoebe Tan
Analyst, Jefferies

Great. Then turning to your general pipeline assets, you have a lot of pipeline assets, a big variety, preclinical and phase I. First, can you talk about the catalyst path moving forward, and might we see data from ZW251, your GPC3 ADC, by year end? I looked at, if you look at ZW191, it kind of came one year after your initiation of the clinical trial, so that would kind of put us at the end of this year for ZW251. I guess any color on timelines there and what you want to see.

Ken Galbraith
CEO, Zymeworks

Yeah, I know there are two answers that sell-side analysts do not like. One is, we just do not provide that type of guidance. I think we try to protect the integrity of the clinical development process and make sure that operates aside from the Wall Street piece. We do think disclosures in peer-reviewed settings is the most relevant way to disclose new clinical data, as opposed to in a press release or some other internal company function.

So, we have to wait for data to intersect with the opportunity for those things to be presented by one of our investigators in a peer-reviewed format. So, it is certainly the case that ZW251 clinical development is going as fast as the other agents we put in, but we do not give any guidance on it. I know until you see an abstract or a title published, that is your guidance. I know people don't like that from the sell side, but we think it's the best way to operate as an R&D company.

I think on clinical and preclinical approaches, we like everything that we're doing inside the company. I think we have a number of clinical assets that are now moving to the stage of being partnerable, like with ZW209, getting clinical data, which I think will drive value, whether we retain that ourselves or choose to partner.

That's more valuable. I think our pan-RAS ADC portfolio that we developed for two years in stealth, that made a first scientific disclosure, has just given us another avenue that I don't think people ever expected to see inside the company. I think that's pretty interesting to have four product candidates just be developed under stealth as a separate research theme.

And if you look at what you've seen recently from us, we had a SITC presentation of our preclinical candidate just a little while ago, which is taking PD-1 VEGF and trying to decide how do you improve upon that. In this case, we've made a trispecific antibody, including IL-7, because I think that's a really interesting construct with PD-1 VEGF. No one else is doing that. That's very unique and differentiator, just trying to move beyond bispecifics to trispecifics in that construct.

Coming up at ASH in December, we'll have our very first heme onc presentation, because we'd like to see how we can look at hematological tumors, not just solid tumors. Our first disclosure actually also happens to be the first disclosure of a pentaspecific antibody for AML, which incorporates three TAAs in a logic gated way with our Co-Stim platform, including CD3 and CD28 and two signals as a T-cell engager.

No one else is doing that, so it just shows the ability of our approach and engineering skills to create really unique, differentiated molecules that hopefully can move into the clinic and provide just a completely different mechanism, completely different clinical benefit from anything else we've seen. So, you can see from an R&D perspective, from clinical agents to even new disclosures this year, we're a continuous innovation organization, and we'll continue to do that year after year.

The idea then is, how do you prosecute that from a business perspective when you think about capital and returns and risk that's maintained by our shareholders versus how much do we share with partners or in spin-off entities.

Phoebe Tan
Analyst, Jefferies

Great. So, on those two that you mentioned, ZW1953, your AML product and then your trispecific PD-1 VEGF IL-7, I guess, what are you trying to differentiate on each specifically, and do you plan to take that into phase I yourself, or would you like to partner those as well?

Ken Galbraith
CEO, Zymeworks

Yeah, I think for us, after we make initial innovation, we're obviously investing in these programs, and we'll make the right decision at some future point as to whether we retain and invest longer or whether we bring in a partner, or if we think we have a portfolio, like with the pan-RAS ADC, that may be better suited to sit in a dedicated entity to get the time, attention, and capital. We can make those decisions as we go along.

They're not predetermined. I think in AML, we're trying to find a way to move that Co-Stim platform to places where a single TAA target just isn't enough. So, we're trying to go beyond trispecifics. We used to think about ourselves as a bispecific antibody engineering company, and then we thought, "Well, maybe we can do more than that." How do you build in more functionality to a bispecific by adding additional arms? Which I know makes it seem like it's adding complexity.

That complexity is not difficult for us from an engineering or development standpoint. So, in this case, in AML, we're just trying to deal with this idea that sometimes one target's not enough. So, obviously, FLT3 is extremely important for this target. It's the initial TAA of interest. But there's two additional target antigens there where we think additional binding may be beneficial. It's controlled, it's conditional, which I think are important elements.

But it's a way for us to build this two signals through CD3, CD28 in a single biologic into a hematological tumor, in this case, AML, because we think there's ways to improve response rate, improve durability with a T-cell engager that goes beyond what we've seen before. We've obviously seen innovation recently in multiple myeloma with dual targeting TCEs that one of our partners, J&J, has done.

I think we're just trying to go beyond that. Pentaspecific sounds very complicated, but adding additional arms just improves functionality and maybe improves clinical benefit. Looking forward to moving that one forward and just seeing if we can see the translation in clinical benefit from what we're excited about from an engineering standpoint.

Phoebe Tan
Analyst, Jefferies

And your PD-1 VEGF IL-7?

Ken Galbraith
CEO, Zymeworks

Yeah, I think PD-1 VEGF, you can certainly see the benefit of that in certain tumor types. I think there's enough of them now available. There's no point creating another bispecific. Our view, though, was, what's the next generation step? Where do you go beyond PD-1 VEGF? How do you improve upon that?

We think this idea of delivering IL-7, which might be an understudied immunocytokine, is just interesting for us to think about. Pre-clinically, you can look at our poster and see that we're doing something unique with adding IL-7. It's not just simply adding a third arm. There's a masking function on the VEGF arm.

So, we're really getting the benefits of PD-1 VEGF, but maybe in a way that's more durable and prolonged and adding activity without straining tolerability, which I think has always been the issue with targeting, being very specific about targeting IL-2 or IL-15 with a PD-1. W e're just going to the next generation of where we think things will get to after PD-1 VEGFs are saturated in the marketplace.

Phoebe Tan
Analyst, Jefferies

Okay.

Ken Galbraith
CEO, Zymeworks

I think that's the type of innovation we always try to do. No one else is really doing that right now, which is a good position to start in. And hopefully, it's too complicated to be easily copied. There's something unique about our platforms that allows us to do that. We've certainly seen that with previous agents. Hopefully, that's the case here.

Phoebe Tan
Analyst, Jefferies

Got it. For your February 11 R&D day, I guess, will we see updated data for these next gens or data from ZW251 or more from ZW191? I guess, what should we expect?

Ken Galbraith
CEO, Zymeworks

Yeah, good question. Agenda to follow. So February 11, New York. We've done an R&D day about every two years. It gives us a chance to highlight some of the capabilities and platforms the company has. We can highlight a few emerging products, whether it's the two more recent ones or something else. I think this time we're also going to try to build in this idea of strategically how we see developing this broad portfolio.

Obviously, I think understanding how we decide to keep things ourselves that are unencumbered with complete upside, but it's all our capital versus partnering versus spin-outs or carve-outs. So try to link the BD strategy with the R&D strategy, maybe a little bit more than we've previously done in R&D events. We'll always try to have something that's surprising, which is the point of people showing up, hopefully.

I think we've obviously made some recent scientific disclosures we can follow up on. We obviously have an idea of what additional work we'd like to disclose next year that we've been working on for a little while, just like we did with pan-RAS ADC at AACR.

So to the extent we can foreshadow a little bit of that, I think we will. If you go back to our December 2024 R&D day, you'll see a little slide in there about targeted small molecules and ADC construct, and that was us starting our pan-RAS inhibitor work without really talking about what the payload was. Sometimes those are good events for people to understand where we're going at a longer-term basis from an innovation standpoint, and this time also a business strategy as well.

Phoebe Tan
Analyst, Jefferies

Got it. On ZW191, your folate receptor alpha ADC, you had updated data at ESMO, and we also saw some data from Rina-S. Can you contextualize ZW191 in the context of the evolving space and where you still think that it really differentiates?

Ken Galbraith
CEO, Zymeworks

Yeah, again, I think from Rina-S, we've seen hazard ratios. I don't think we've seen any data yet. It'd be nice to understand the data that supports those hazard ratios that were disclosed. Eventually, we'll see that. I think ZW191 is doing exactly what we thought it would do when we designed it, with a more moderate topo payload and with a unique epitope on the antibody, which is a strong internalizer.

You can certainly see in our data that there is a relationship between activity in ORR and the expression profile of that biomarker, folate receptor alpha, and we think that's the way that ADCs should work.

What you've seen the past couple of years in gynecological tumors, both ovarian and endometrial, is almost all of them work regardless of the selection that you made. Regardless of antibody, whether it's folate receptor alpha, NaPi2b, CDH6, others, regardless of linker strategy, regardless of whether the payload is more potent or less potent, almost every single one of them drives a reasonable amount of activity in those tumor types and has its own particular tolerability issues.

But almost all of them work, which is great for patients. That's a harder place to make R&D differentiation. So those areas become situations where commercial differentiation becomes much more relevant, which certainly drives our thoughts that it's a really great agent. I think some of these later agents, like ours and a few others, have maybe a little bit better activity coming a little bit later.

But certainly, it's hard to see how we can compete in a registration strategy in a commercial environment without a partner helping us do that. I think it has done exactly what we designed it to do. It is definitely a much more crowded marketplace with a lot more competition and a lot less R&D differentiation than maybe we see in some of our other assets we developed. A great partner, I think, can make the most out of the attributes of ZW191, but probably more from commercial differentiation than with R&D differentiation.

Phoebe Tan
Analyst, Jefferies

Got it. When we have two minutes left.

Ken Galbraith
CEO, Zymeworks

Yeah, sorry.

Phoebe Tan
Analyst, Jefferies

On zani, I guess we saw some data at ESMO, your second interim OS data, and there was some variability in the subgroup analysis for the doublet. Looking at kind of launch and how you look at the triplet versus the doublet, can you talk about where you expect uptake to be initially more successful for the doublet and then for the triplet as well?

Ken Galbraith
CEO, Zymeworks

That's great. I can't believe you left zanidatamab to the end, but thank you. What an amazing molecule. I mean, this year we had the benefit of being involved with a molecule that we created, which moved median OS for this patient population by more than seven or eight months, which is pretty amazing on the median. Being able to replace something as standard of care, like Herceptin had been the standard of care for 12 years.

I mean, that's why we do this, because the impact on patients will be dramatic. It's also economically very interesting for our partners, Jazz and BeOne and ourselves. So now we're looking at peak sales estimates of $3 billion-$5 billion for zanidatamab, which I think we always felt back in 2022 was something that this had the potential.

But obviously, getting to this point, you have a lot more ability to have validation of that through clinical data, and now we'll see what happens with launch. Having the ability to do both doublet and triplet combinations just shows that focusing on tolerability while you drive activity in these agents, and we do it everywhere, not just zanidatamab, becomes extremely important.

So this ability to have immunotherapy, zanidatamab as the innovative HER2 agent, and a double chemo regimen be tolerable in all combination is what's driving these long-term benefits for patients. So this focus on tolerability while you drive better activity is extremely important, and that was designed into the molecule from day one as a focus.

Obviously, the triplet seems to have, at least in the clinical studies, a longer treatment duration, which I think from a commercial perspective means for a patient, you probably have a longer treatment duration. You have more vials being consumed by that patient on a triplet than a doublet. We'll have to see how that works in the real world, but certainly the clinical data from the study indicates that.

But it's pretty amazing to be involved with this type of scientific innovation and finding a way to get it to market, realizing the benefit for patients, and then seeing also that benefit be provided to our shareholders who provided the risk capital to get this far, and for our partners, BeOne and Jazz, who also provided the risk capital to get it to this stage. So we're just excited to do that again and again and again.

That is just kind of the way that we try to operate inside the company. We certainly have inklings of things with pasritamig and others to follow, where it seems like we will be able to use our innovation to do this multiple times.

Phoebe Tan
Analyst, Jefferies

Mm-hmm. Then lastly, I will sneak a last one in. For your there is pipeline, there is pan-tumor 206 study, then it could be potentially registrational, then also the post in HER2 trial. Maybe just set up what we might see over the coming years. I know that EmpowHER-303 trial might read out late 2027, early 2028, so kind of what we should expect there.

Ken Galbraith
CEO, Zymeworks

Yeah, we have a pan-tumor study that will be reading out. I think primary completion on clinical trials is December 31st this year, so it is another opportunity for a tumor agnostic label as well as some other data around other indications. There is another randomized study for zani going to read out in a reasonable time period, which might show that we can certainly improve upon trastuzumab in the post-HER2 patient population.

It opens up another amazing ability to help a large group of patients with zani in combination with chemotherapy versus trastuzumab and chemotherapy in the post-HER2 population. So that is pretty exciting for Jazz and BeOne and ourselves. It is not that far away. It is binary. It is a randomized study. Just because we worked in GEA in a randomized study does not mean it will work in every tumor indication, so we have to realize it is binary.

But we have to be optimistic based on everything we have seen from the totality of zani data right now, that we will be able to provide another option for patients, which will improve upon what they might have in that post-HER2 patient population. It is not that far away. We also have the first phase III study from pasritamig reading out next year from J&J in prostate cancer. So these binary events keep coming at us and hopefully end up on the positive side of the ledger from those studies.

Phoebe Tan
Analyst, Jefferies

Perfect. Thank you so much.

Ken Galbraith
CEO, Zymeworks

That is great. Thank you very much. Thank you.